Inventor · disambiguated record
Nicholas R. Wurtz
Also filed as: WURTZ NICHOLAS · WURTZ NICHOLAS R · WURTZ NICHOLAS RONALD
21 granted patents·6 pending applications·45 citations·filing 2001–2022
92Inventor score
Top patents by PatentIndex Score
27 records- 0188US10676431B2Phenylpyrrolidinone formyl peptide 2 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 9, 2020·6 cites·53 claims
- 0286US9174974B2Macrocyclic factor VIIa inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Nov 3, 2015·5 cites·9 claims
- 0385US11117861B2Phenylpyrrolidinone formyl peptide 2 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Sep 14, 2021·2 cites·15 claims
- 0484US11708327B2Phenylpyrrolidinone formyl peptide 2 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jul 25, 2023·1 cites·16 claims
- 0584US10717708B2Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 21, 2020·3 cites·12 claims
- 0683US6559125B1Polyamide-alkylator conjugates and related products and methodCALIFORNIA INST OF TECHN·Filed 2001·Granted May 6, 2003·17 cites·31 claims
- 0782US7592331B2Macrocyclic factor VIIa inhibitors useful as anticoagulantsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Sep 22, 2009·5 cites·25 claims
- 0880US11186544B2Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 30, 2021·2 cites·6 claims
- 0972US11008301B2Piperidinone formyl peptide 2 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted May 18, 2021·1 cites·9 claims
- 1070US9920075B2Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Mar 20, 2018·1 cites·9 claims
- 1166US8420830B2Macrocyclic factor VIIa inhibitors useful as anticoagulantsWURTZ NICHOLAS RONALD·Filed 2007·Granted Apr 16, 2013·2 cites·17 claims
- 1261US11530183B2Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Dec 20, 2022·0 cites·12 claims
- 1358US2025221966A1Rxfp1 agonistsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1453US12281108B2Pyrrolidinone derivatives as formyl peptide 2 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Apr 22, 2025·0 cites·7 claims
- 1551US10981879B2Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 20, 2021·0 cites·5 claims
- 1650US2022298186A1Biaryl dialkyl phosphine oxide fpr2 agonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1749US2023348426A1Oxopyrrolidine fpr2 agonistsBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1848US11180490B2Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 23, 2021·0 cites·12 claims
- 1947US8039506B2Bicyclic lactam factor VIIa inhibitors useful as anticoagulantsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Oct 18, 2011·0 cites·16 claims
- 2047US2020069644A1Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failureBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 2142US9834542B2LXR modulatorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Dec 5, 2017·0 cites·19 claims
- 2241US11124494B2Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Sep 21, 2021·0 cites·7 claims
- 2341US2017247343A1Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 2438US11008317B2Triazolopyridine inhibitors of myeloperoxidase and/or EPXBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 18, 2021·0 cites·5 claims
- 2537US10316035B2Triazolopyridine inhibitors of myeloperoxidaseBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 11, 2019·0 cites·9 claims
- 2637US9751869B2LXR modulatorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 5, 2017·0 cites·19 claims
- 2737US2018325869A1Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart diseaseBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nicholas R. Wurtz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →